As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Dr. Mario Castro, for a webinar on “Severe Asthma Data in SARP” on 19 June, 2018.
Please note: Unpublished data slides have been redacted from the webinar recording at the request of Dr. Castro.
Dr. Castro presents findings from the Severe Asthma Research Program (SARP), providing insights into severe asthma disease phenotypes and approaches for targeted therapy.
The SARP network links 7 asthma clinical university centres and 1 data coordinating centre in the USA, sponsored by the National Institutes of Health (NIH). The SARP network has been operational for 2 decades and the current 3rd phase (SARP III) has enrolled over 700 participants. The SARP network’s mission is to “improve the understanding of severe asthma in order to develop better treatments.”
Dr. Castro highlights the use of imaging technologies to better understand the lung changes that occur in severe asthma. His findings identify subgroups of patients with specific changes in the lung. The hope is that identification of these subgroups will inform the use of targeted therapies.
Dr. Castro also presents data on the effects of dupilumab treatment. Dupilumab is a monoclonal antibody that targets IL-4 receptor alpha (anti-IL-4Ra). Recent clinical trials published in the New England Journal of Medicine showed that dupilumab treatment improves patient outcomes.
About Dr. Mario Castro:
Dr. Castro is the Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine at the Washington University School of Medicine (St Louis, MO).
Dr Castro’s specialties include asthma and related allergic disease, COPD, emphysema, chronic bronchitis, chronic cough and unexplained shortness of breath. Dr Castro is active in research and is working under several grants from the National Institutes of Health (NIH) regarding the causes of asthma, especially severe asthma, as part of the Severe Asthma Research Program (SARP).
He is the Principal Investigator of several networks sponsored by the NIH, Patient-Centered Outcomes Research Institute and American Lung Association, evaluating the management and treatment of asthma and airway diseases. He has been a Member of the Scientific Advisory Board at Therabron Therapeutics, Inc. since May 19 2016. He is the recipient of numerous awards and is author or co-author of more than 200 peer reviewed articles.
Dr. Mario Castro’s travel was supported by AstraZeneca